View Item 

Show simple item record

The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study
dc.contributor.authorKjeldsen, Sverre E.en_US
dc.contributor.authorLyle, Paulette A.en_US
dc.contributor.authorKizer, Jorge R.en_US
dc.contributor.authorDahlof, Bjornen_US
dc.contributor.authorDevereux, Richard B.en_US
dc.contributor.authorJulius, Stevoen_US
dc.contributor.authorBeevers, Garethen_US
dc.contributor.authorFaire, Ulf deen_US
dc.contributor.authorFyhrquist, Frejen_US
dc.contributor.authorIbsen, Hansen_US
dc.contributor.authorKristianson, Kristeren_US
dc.contributor.authorLederballe-Pedersen, Oleen_US
dc.contributor.authorLindholm, Lars H.en_US
dc.contributor.authorNieminen, Markku S.en_US
dc.contributor.authorOmvik, Peren_US
dc.contributor.authorOparil, Suzanneen_US
dc.contributor.authorSnapinn, Steven M.en_US
dc.contributor.authorHarris, Katherine E.en_US
dc.contributor.authorWedel, Hansen_US
dc.date.accessioned2010-06-01T19:43:29Z
dc.date.available2010-06-01T19:43:29Z
dc.date.issued2005-03en_US
dc.identifier.citationKjeldsen, Sverre E . ; Lyle, Paulette A . ; Kizer, Jorge R . ; Dahlof, Bjorn; Devereux, Richard B . ; Julius, Stevo; Beevers, Gareth; Faire, Ulf de; Fyhrquist, Frej; Ibsen, Hans; Kristianson, Krister; Lederballe-Pedersen, Ole; Lindholm, Lars H . ; Nieminen, Markku S . ; Omvik, Per; Oparil, Suzanne; Snapinn, Steven M . ; Harris, Katherine E . ; Wedel, Hans (2005). "The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study." The Journal of Clinical Hypertension 7(3): 152-158. <http://hdl.handle.net/2027.42/72858>en_US
dc.identifier.issn1524-6175en_US
dc.identifier.issn1751-7176en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72858
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15785156&dopt=citationen_US
dc.format.extent156692 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherLe Jacq Ltd.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.rights2005 Le Jacq Ltd.en_US
dc.titleThe Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOncology and Hematologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arbor, MI;en_US
dc.contributor.affiliationotherFrom the Ullevaal University Hospital, Oslo, Norway;en_US
dc.contributor.affiliationotherMerck & Co., Inc., Whitehouse Station, Nj;en_US
dc.contributor.affiliationotherWeill Medical College of Cornell University, New York, NY;en_US
dc.contributor.affiliationotherSahlgrenska/ Ostra University Hospital, Gothenburg, Sweden;en_US
dc.contributor.affiliationotherCity Hospital, Birmingham, UK;en_US
dc.contributor.affiliationotherKarolinska University Hospital, Stockholm, Sweden-en_US
dc.contributor.affiliationotherHelsinki University Central Hospital, Finland;en_US
dc.contributor.affiliationotherGlostrup University Hospital, Copenhagen, Denmark;en_US
dc.contributor.affiliationotherMerck Research Laboratories Scandinavia, Stockholm, Sweden;en_US
dc.contributor.affiliationotherViborg Hospital, Denmark;en_US
dc.contributor.affiliationotherUmed University, Sweden;en_US
dc.contributor.affiliationotherHaukeland University Hospital, Bergen, Norway;en_US
dc.contributor.affiliationotherUniversity of Alabama at Birmingham, Birmingham, AL;en_US
dc.contributor.affiliationotherThe Nordic School of Public Health, Gothenburg, Swedenen_US
dc.identifier.pmid15785156en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72858/1/j.1524-6175.2005.04254.x.pdf
dc.identifier.doi10.1111/j.1524-6175.2005.04254.xen_US
dc.identifier.sourceThe Journal of Clinical Hypertensionen_US
dc.identifier.citedreferenceMurray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 1997; 349: 1436 – 1442.en_US
dc.identifier.citedreferenceMurray CJL, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997; 349: 1269 – 1276.en_US
dc.identifier.citedreference3 American Heart Association. Heart Disease and Stroke Statistics-2004 Update. Dallas, TX: American Heart Association; 2003.en_US
dc.identifier.citedreference4 International Database (IDB). U.S. Census Bureau. Available at: http://www.census.gov/ipc/www/idbnew.html. Accessed December 1, 2004.en_US
dc.identifier.citedreferenceMoser M. Social and economic implications of stroke prevention. J Public Health Policy. 1984; 2: 228 – 237.en_US
dc.identifier.citedreferenceBronner LL, Kanter DS, Manson JE. Primary prevention of stroke. N Engl J Med. 1995; 333: 1392 – 1400.en_US
dc.identifier.citedreferenceLawes CM, Bennett DA, Feigin VL, et al. Blood pressure and stroke: an overview of published reviews. Stroke. 2004; 35: 776 – 785.en_US
dc.identifier.citedreferenceDahlÖf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995 – 1003.en_US
dc.identifier.citedreferenceKizer J, DahlÖf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the LIFE study. Hypertension. 2005; 45: 46 – 52.en_US
dc.identifier.citedreferenceKannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease: the Framingham Study. Am J Cardiol. 1971; 27: 335 – 346.en_US
dc.identifier.citedreferenceKannel WB, Wolfe PA, McGee DL. Systolic blood pressure, arterial rigidity and risk of stroke: the Framingham Study. JAMA. 1981; 245: 1225 – 1229.en_US
dc.identifier.citedreference12 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older subjects with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255 – 3264.en_US
dc.identifier.citedreferenceStaessen JA, Fagard R, Thijs L, et al. Randomized doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997; 350: 757 – 764.en_US
dc.identifier.citedreferenceLiu L, Wang JG, Gong L, et al., for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. J Hypertens. 1998; 16: 1823 – 1829.en_US
dc.identifier.citedreferenceDahlÖf B, Devereux RB, Julius S, et al. Characteristics of 9,194 patients with left ventricular hypertrophy. The LIFE Study. Hypertension. 1998; 32: 989 – 997.en_US
dc.identifier.citedreferenceLindholm LH, Ibsen H, DahlÖf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 1004 – 1010.en_US
dc.identifier.citedreferenceWolf PA, D'Agostino RB, O'Neal MA, et al. Secular trends in stroke incidence and mortality. The Framingham Study. Stroke. 1992; 23: 1551 – 1555.en_US
dc.identifier.citedreferenceKjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention For Endpoint Reduction (LIFE) substudy. JAMA. 2002; 288: 1491 – 1498.en_US
dc.identifier.citedreferenceOkin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in Hypertension (LIFE) study. Circulation. 2003; 108: 684 – 690.en_US
dc.identifier.citedreferenceDevereux RB, DahlÖf B, Gerdts E, et al. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation. 2004; 110: 1456 – 1462.en_US
dc.identifier.citedreferenceVerdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation. 2001; 104: 2039 – 2044.en_US
dc.identifier.citedreferenceDevereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension: JAMA. 2004; 292: 2350 – 2356.en_US
dc.identifier.citedreferencePapademetriou V, Wachtell K, Gerdts E, et al. Left ventricular mass changes in patients with isolated systolic or combined hypertension and echocardiographic left ventricular hypertrophy: the LIFE study [abstract]. Am J Hypertens. 2003; 16 ( 5 pt 2 ): 126A – 127A.en_US
dc.identifier.citedreferenceWachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the LIFE study. J Am Coll Cardiol. In press.en_US
dc.identifier.citedreferenceWachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol. In press.en_US
dc.identifier.citedreferenceChabielska E, Matys T, Kucharewicz I, et al. The involvement of AT(2)-receptor in the antithrombotic effect of losartan in renal hypertensive rats. J Renin Angiotensin Aldosterone Syst. 2000; 1: 263 – 267.en_US
dc.identifier.citedreferenceLÓpez-FarrÉ A, SÁnchez de Miguel L, MontÓn M, et al. Angiotensin II AT1 receptor antagonists and platelet activation. Nephrol Dial Transplant. 2001; 16: 45 – 49.en_US
dc.identifier.citedreferenceKucharewicz I, Pawlak R, Matys T, et al. Antithrombotic effect of captopril and losartan is mediated by angiotensin (1-7). Hypertension. 2002; 40: 774 – 779.en_US
dc.identifier.citedreferenceMahmud A, Feely J. Effect of angiotensin II receptor blockade on arterial stiffness: beyond blood pressure reduction. Am J Hypertens. 2002; 15: 1092 – 1095.en_US
dc.identifier.citedreferenceAchard J, Fournier A, Mazouz H, et al. Protection against ischemia: a physiological function of the renin-angiotensin system. Biochem Pharmacol. 2001; 62: 261 – 271.en_US
dc.identifier.citedreferenceFournier A, Achard JM, Boutitie F, et al. Is the angiotensin II Type 2 receptor cerebroprotective ? Curr Hypertens Rep. 2004; 6: 182 – 189.en_US
dc.identifier.citedreferenceBosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomized trial. BMJ. 2002; 324: 1 – 5.en_US
dc.identifier.citedreferenceSleight P, Yusuf S, Pogue J, et al. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet. 2001; 358: 2130 – 2131.en_US
dc.identifier.citedreferenceSvensson P, de Faire U, Sleight P, et al. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension. 2001; 38: E28 – E32.en_US
dc.identifier.citedreferenceHoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004; 65: 1041 – 1049.en_US
dc.identifier.citedreferencePapademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004; 44: 1175 – 1180.en_US
dc.identifier.citedreferenceDahlÖf B, Burke TA, Krobot K, et al. Population impact of losartan use on stroke in the European Union (EU): projections from the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. J Human Hypertens. 2004; 18: 367 – 373.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1524-6175.2005.04254.x.pdf
Size:
153.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.